Clinical characteristics of patients in the study
| . | Cutaneous lymphoma (n = 63) . | Benign skin disease or normal skin (n = 85) . | P . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MF (n = 39) . | SS (n = 7) . | CALCL (n = 8) . | NOS (n = 9) . | Σ . | AD (n = 20) . | ND (n = 4) . | PP (n = 42) . | PN (n = 17) . | NN (n = 2) . | Σ . | ||
| Age, y* | < .001 | |||||||||||
| Younger than 30 | 0 | 0 | 1 | 0 | 1 | 19 | 0 | 4 | 4 | 2 | 29 | |
| 30-44 | 5 | 0 | 0 | 0 | 5 | 1 | 0 | 6 | 3 | 0 | 10 | |
| 45-59 | 9 | 1 | 1 | 2 | 13 | 0 | 1 | 19 | 7 | 0 | 27 | |
| 60-74 | 14 | 6 | 2 | 2 | 24 | 0 | 3 | 12 | 2 | 0 | 17 | |
| Older than 75 | 10 | 0 | 2 | 5 | 17 | 0 | 0 | 1 | 1 | 0 | 2 | |
| Sex* | .999 | |||||||||||
| Male | 23 | 7 | 5 | 5 | 40 | 8 | 1 | 30 | 16 | 2 | 57 | |
| Female | 15 | 0 | 1 | 4 | 20 | 12 | 3 | 12 | 1 | 0 | 28 | |
| Microarray batch | .999 | |||||||||||
| 1 | 8 | 2 | 1 | 2 | 13 | 4 | 1 | 8 | 3 | 1 | 17 | |
| 2 | 7 | 2 | 2 | 1 | 12 | 4 | 1 | 8 | 3 | 1 | 17 | |
| 3 | 7 | 1 | 2 | 2 | 12 | 4 | 1 | 8 | 3 | 0 | 16 | |
| 4 | 9 | 1 | 2 | 2 | 14 | 4 | 0 | 9 | 4 | 0 | 17 | |
| 5 | 8 | 1 | 1 | 2 | 12 | 4 | 1 | 9 | 4 | 0 | 18 | |
| . | Cutaneous lymphoma (n = 63) . | Benign skin disease or normal skin (n = 85) . | P . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MF (n = 39) . | SS (n = 7) . | CALCL (n = 8) . | NOS (n = 9) . | Σ . | AD (n = 20) . | ND (n = 4) . | PP (n = 42) . | PN (n = 17) . | NN (n = 2) . | Σ . | ||
| Age, y* | < .001 | |||||||||||
| Younger than 30 | 0 | 0 | 1 | 0 | 1 | 19 | 0 | 4 | 4 | 2 | 29 | |
| 30-44 | 5 | 0 | 0 | 0 | 5 | 1 | 0 | 6 | 3 | 0 | 10 | |
| 45-59 | 9 | 1 | 1 | 2 | 13 | 0 | 1 | 19 | 7 | 0 | 27 | |
| 60-74 | 14 | 6 | 2 | 2 | 24 | 0 | 3 | 12 | 2 | 0 | 17 | |
| Older than 75 | 10 | 0 | 2 | 5 | 17 | 0 | 0 | 1 | 1 | 0 | 2 | |
| Sex* | .999 | |||||||||||
| Male | 23 | 7 | 5 | 5 | 40 | 8 | 1 | 30 | 16 | 2 | 57 | |
| Female | 15 | 0 | 1 | 4 | 20 | 12 | 3 | 12 | 1 | 0 | 28 | |
| Microarray batch | .999 | |||||||||||
| 1 | 8 | 2 | 1 | 2 | 13 | 4 | 1 | 8 | 3 | 1 | 17 | |
| 2 | 7 | 2 | 2 | 1 | 12 | 4 | 1 | 8 | 3 | 1 | 17 | |
| 3 | 7 | 1 | 2 | 2 | 12 | 4 | 1 | 8 | 3 | 0 | 16 | |
| 4 | 9 | 1 | 2 | 2 | 14 | 4 | 0 | 9 | 4 | 0 | 17 | |
| 5 | 8 | 1 | 1 | 2 | 12 | 4 | 1 | 9 | 4 | 0 | 18 | |
Indications are stratified according to age, sex, and the microarray production batch. P values were calculated using Fisher's exact test on sums across subindications (the Σ columns).
CALCL indicates cutaneous anaplastic large cell lymphoma; AD, atopic dermatitis; ND, unspecified dermatosis; PP, lesional skin from psoriasis patients; PN, nonlesional skin from psoriasis patients; and NN, normal skin from healthy controls.
Sex and age of 2 CALC and 1 MF samples are unknown.